{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:37:06Z","timestamp":1788053826612,"version":"build-2784847793"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T00:00:00Z","timestamp":1319155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>For premenopausal patients with receptor-positive early breast cancer, administration of tamoxifen for 5 years constitutes the main adjuvant endocrine therapy. During pregnancy, tamoxifen and its metabolites interact with rapidly growing and developing embryonic or fetal tissues.<\/jats:p>\n               <jats:p>Information about tamoxifen and pregnancy was gathered by searching PubMed. In addition, we had access to the records of the pharmaceutical company AstraZeneca. Because these observations are retrospective and other therapies and diagnostic measures are possible confounders, a causal relationship was not established between tamoxifen treatment and pregnancy outcome.<\/jats:p>\n               <jats:p>The records from AstraZeneca documented three live births with congenital anomalies and four live births without congenital anomalies related to tamoxifen treatment before pregnancy. Tamoxifen therapy during pregnancy resulted in 16 live births with congenital malformations and a total of 122 live births without malformations. The 122 live births without malformations included 85 patients from a prevention trial that did not record a single anomaly, whereas the AstraZeneca Safety Database alone reported 11 babies with congenital malformations of 44 live births. Additionally, there were: 12 spontaneous abortions, 17 terminations of pregnancy without known fetal defects, six terminations of pregnancy with fetal defects, one stillbirth without fetal defects, two stillbirths with fetal defects, and 57 unknown outcomes.<\/jats:p>\n               <jats:p>The relatively high frequency of severe congenital abnormalities indicates that reliable birth control during tamoxifen treatment is mandatory. After tamoxifen use, a washout period of 2 months is advisable based on the known half-life of tamoxifen. In case of an inadvertent pregnancy, risks and options should be discussed.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-0121","type":"journal-article","created":{"date-parts":[[2011,10,22]],"date-time":"2011-10-22T03:32:58Z","timestamp":1319254378000},"page":"1547-1551","source":"Crossref","is-referenced-by-count":125,"title":["Use of Tamoxifen Before and During Pregnancy"],"prefix":"10.1093","volume":"16","author":[{"given":"Geert","family":"Braems","sequence":"first","affiliation":[{"name":"a Department of Gynecologic Oncology, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Denys","sequence":"additional","affiliation":[{"name":"b Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"De Wever","sequence":"additional","affiliation":[{"name":"c Laboratory for Cancer Research, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Cocquyt","sequence":"additional","affiliation":[{"name":"b Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"Van den Broecke","sequence":"additional","affiliation":[{"name":"a Department of Gynecologic Oncology, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,10,21]]},"reference":[{"key":"2021122304030714100_B1","first-page":"465","article-title":"Breast cancer in women under 40","volume":"23","author":"Peppercorn","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"2021122304030714100_B2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1634\/theoncologist.11-5-422","article-title":"Fertility preservation in young women undergoing breast cancer therapy","volume":"11","author":"Sonmezer","year":"2006","journal-title":"The Oncologist"},{"key":"2021122304030714100_B3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: A most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2021122304030714100_B4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0093-7754(01)90133-2","article-title":"Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience","volume":"28","author":"Fisher","year":"2001","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"2021122304030714100_B5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00280-005-0108-2","article-title":"Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: Implicated role of growth factor signaling and estrogen receptor coregulators","volume":"56","author":"Schiff","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122304030714100_B6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/jpet.104.065607","article-title":"Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6","volume":"310","author":"Desta","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122304030714100_B7","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S1470-2045(05)70388-0","article-title":"Modulation of cytochrome P450 activity: Implications for cancer therapy","volume":"6","author":"Scripture","year":"2005","journal-title":"Lancet Oncol"},{"key":"2021122304030714100_B8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1124\/jpet.105.100511","article-title":"Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells","volume":"318","author":"Lim","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122304030714100_B9","first-page":"89","article-title":"Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response","volume":"1","author":"Patterson","year":"1980","journal-title":"Eur J Cancer Suppl"},{"key":"2021122304030714100_B10","first-page":"1629","article-title":"Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours","volume":"82","author":"MacCallum","year":"2000","journal-title":"Br J Cancer"},{"key":"2021122304030714100_B11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0046-8177(87)80381-7","article-title":"Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract","volume":"18","author":"Cunha","year":"1987","journal-title":"Hum Pathol"},{"key":"2021122304030714100_B12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(97)24029-8","article-title":"Ambiguous genitalia in infant exposed to tamoxifen in utero","volume":"350","author":"Tewari","year":"1997","journal-title":"Lancet"},{"key":"2021122304030714100_B13","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1001\/jama.1994.03510480029019","article-title":"Goldenhar's syndrome associated with tamoxifen given to the mother during gestation","volume":"271","author":"Cullins","year":"1994","journal-title":"JAMA"},{"key":"2021122304030714100_B14","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/ajmg.a.32432","article-title":"Pierre Robin sequence associated with first trimester fetal tamoxifen exposure","volume":"146A","author":"Berger","year":"2008","journal-title":"Am J Med Genet A"},{"key":"2021122304030714100_B15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0301-2115(01)00552-8","article-title":"An infertile patient with breast cancer who delivered a healthy child under adjuvant tamoxifen therapy","volume":"104","author":"\u00d6ks\u00fczoglu","year":"2002","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2021122304030714100_B16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0015-0282(16)49531-2","article-title":"Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas","volume":"46","author":"Koizumi","year":"1986","journal-title":"Fertil Steril"},{"key":"2021122304030714100_B17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/gyno.2000.6080","article-title":"Tamoxifen as systemic treatment of advanced breast cancer during pregnancy\u2014case report and literature review","volume":"80","author":"Isaacs","year":"2001","journal-title":"Gynecol Oncol"},{"key":"2021122304030714100_B18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0140-6736(93)91361-O","article-title":"Prophylactic tamoxifen","volume":"342","author":"Clark","year":"1993","journal-title":"Lancet"},{"key":"2021122304030714100_B19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.breast.2004.08.007","article-title":"Tamoxifen and pregnancy","volume":"13","author":"Barthelmes","year":"2004","journal-title":"Breast"},{"key":"2021122304030714100_B20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3816\/CBC.2006.n.031","article-title":"Pregnancy after the diagnosis of breast cancer","volume":"7","author":"Morrow","year":"2006","journal-title":"Clin Breast Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0121","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/11\/1547\/41855945\/oncolo_16_11_1547.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/11\/1547\/41855945\/oncolo_16_11_1547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T11:32:32Z","timestamp":1640259152000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/11\/1547\/6400748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,21]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2011,10,21]]},"published-print":{"date-parts":[[2011,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0121","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,11,1]]},"published":{"date-parts":[[2011,10,21]]}}}